Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus SOX perioperative study in resectable gastric and gastroesophageal junction adenocarcinoma
ChiCTR2200065729Phase 4Not yet recruiting
- Sponsor
- Jiaozuo No.2 People's Hospital
- Start
- Oct 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab, oxaliplatin and tegafur + gimeracil + oteracil in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Jiaozuo No.2 People's Hospital. Primary endpoint: Major pathologic response. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
camrelizumaboxaliplatintegafur + gimeracil + oteracil
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2200065729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065729.